Publication date: May 02, 2025
Despite the higher specificity and reliability of detecting latent tuberculosis infection, Mycobacterium tuberculosis-specific interferon (IFN)-γ release assays do not perform satisfactorily in predicting the risk of active TB development. It is crucial to identify new biomarkers with high predictive accuracy to identify individuals bearing a high risk of progression. This was a sub-study of an open label, randomized clinical trial for prevention of TB in silicosis patients. Twenty-six participants were diagnosed with active TB within 37 months’ follow-up. They were defined as TB progressors and matched in a 1:2 ratio with 52 TB non-progressors. We analyzed expression of 45 cytokines in QuantiFERON supernatants from TB progressors and non-progressors, and granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, interleukin (IL)-3, IFN-γ-induced protein 10 (IP-10), IL-10, and IL-9 outperformed IFN-γ as predictive markers. These findings highlight the potential of new biomarkers in identifying individuals with high risk of tuberculosis to undergo early intervention. ClinicalTrials. gov number: NCT02430259.
| Concepts | Keywords |
|---|---|
| Clinicaltrials | cytokines |
| Mycobacterium | diagnosis |
| Nct02430259 | immunological detection |
| Outperformed | tuberculosis |
| Tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| pathway | REACTOME | Release |
| disease | MESH | silicosis |
| disease | IDO | protein |
| drug | DRUGBANK | Interleukin-10 |
| disease | IDO | intervention |